Virgin Herbert 4
4 · Vir Biotechnology, Inc. · Filed Jan 13, 2022
Insider Transaction Report
Form 4
Virgin Herbert
EVP, Research & CSO
Transactions
- Exercise/Conversion
Stock Option (Right to Buy)
2022-01-11−1,375→ 223,630 totalExercise: $1.53Exp: 2028-01-26→ Common Stock (1,375 underlying) - Exercise/Conversion
Common Stock
2022-01-11$1.53/sh+1,375$2,104→ 109,075 total - Sale
Common Stock
2022-01-11$35.10/sh−1,375$48,263→ 107,700 total
Footnotes (2)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 26, 2021.
- [F2]The option is fully vested and exercisable.